NRx Pharmaceuticals (NRXP) and its wholly-owned subsidiary HOPE Therapeutics, a multi-site clinical care delivery organization, signed a binding Letter of Intent to purchase a 49% interest in Cohen and Associates. Cohen is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida. Cohen offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation as well as medication management. The potential acquisition of Cohen is subject to the execution of definitive transaction documents and standard closing requirements. Further details regarding the terms of the transaction will be disclosed at that time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals announces filing for FDC’s NPV program on behalf of NRX-100
- NRx Pharmaceuticals files $150M mixed securities shelf
- NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners
- NRX Pharmaceuticals Submits FDA Application for NRX-100
- NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network